Breaking Down Xi'an International Medical Investment Company Limited Financial Health: Key Insights for Investors

Dive into Xi'an International Medical Investment's financial picture: 2024 revenue reached CNY 4.82 billion (up 4.28% from CNY 4.62 billion) while TTM revenue as of June 2025 was CNY 4.33 billion, revenue per employee stands at CNY 500,035 across 8,858 staff and PS ratio is 2.75 vs. an industry median of 1.58; profitability remains strained with a 2024 net loss of CNY 254 million, TTM net profit margin of -5.65%, EPS (TTM Jun 2025) of -CNY 0.15, ROE -10.50% and ROA -1.58% though EBITDA (TTM Jun 2025) is CNY 417.63 million (EBITDA margin ~9.5%); balance sheet and liquidity flags include total assets of CNY 10.01 billion, total liabilities CNY 6.80 billion, total debt CNY 4.45 billion (debt/equity 1.39), current ratio 0.28 and quick ratio 0.25 with cash and short-term investments at CNY 413.15 million (down 42.18%), while enterprise value is CNY 14.64 billion (EV/EBITDA 35.06) and market cap as of Aug 1, 2025 is CNY 12.25 billion (up 15.64% Y/Y); investors weighing risk versus upside should note the steep liquidity pressure-interest coverage -1.66 and operating income (TTM) -CNY 261.53 million-against analyst forecasts of 88.3% annual earnings growth and 14.6% annual revenue growth over the next three years, plus strategic moves including potential CNY 300 million in joint-venture investments and a ~30% potential increase in product reach.

Xi'an International Medical Investment Company Limited (000516.SZ) - Revenue Analysis

• 2024 revenue: CNY 4.82 billion (+4.28% vs 2023)
• 2023 revenue: CNY 4.62 billion
• TTM revenue (Jun 2025): CNY 4.33 billion (slight decline from prior TTM)

• Employees: 8,858
• Revenue per employee: CNY 500,035
• Revenue per share (PS Ratio): 2.75 (industry median: 1.58)
• Market capitalization (Aug 1, 2025): CNY 12.25 billion (+15.64% over past year)

Xi'an International Medical Investment Company Limited (000516.SZ) - Profitability Metrics

• Net loss (2024): CNY 254.00 million (improved 31.01% vs. 2023 loss of CNY 335.68 million).
• Trailing twelve months (TTM) ending June 2025 net profit margin: -5.65%.
• TTM ending June 2025 EPS: -CNY 0.15 per share.
• Return on equity (ROE): -10.50%.
• Return on assets (ROA): -1.58%.
• TTM ending June 2025 operating income: -CNY 261.53 million.
• TTM ending June 2025 EBITDA: CNY 417.63 million; EBITDA margin: ~9.5%.

• EBITDA vs. operating income indicates positive underlying cash-generation potential despite negative operating profitability.
• Negative margins, EPS, ROE and ROA signal continued losses and capital inefficiency; improvement in 2024 net loss is a positive directional sign.
• Investors should weigh EBITDA strength against recurring operating losses and balance-sheet returns when assessing valuation and turnaround prospects.

Xi'an International Medical Investment Company Limited (000516.SZ) - Debt vs. Equity Structure

• High leverage: debt-to-equity of 1.39 indicates the company relies significantly on debt financing relative to equity (CNY 4.45bn debt vs. CNY 3.21bn equity).
• Weak liquidity: current ratio 0.28 and quick ratio 0.25 signal potential short-term funding stress to cover current liabilities.
• Negative operating coverage: interest coverage of -1.66 reflects negative EBIT, increasing refinancing and solvency risk.
• Valuation tension: EV/EBITDA of 35.06 with EV at CNY 14.64bn suggests market valuation is high relative to current cash earnings.

For additional context on shareholders, trading dynamics and who's buying, see: Exploring Xi'an International Medical Investment Company Limited Investor Profile: Who's Buying and Why?

Xi'an International Medical Investment Company Limited (000516.SZ) - Liquidity and Solvency

Key liquidity and solvency metrics for the quarter ending June 2025 indicate tighter short-term liquidity but stronger operating cash generation versus prior year. Below are the core figures and their immediate implications.

• Cash & short-term investments: CNY 413.15 million (down 42.18% vs. prior period).
• Net change in cash (Q2 2025): -CNY 103.79 million (down 38.56% YoY).
• Free cash flow (Q2 2025): CNY 302.84 million (up 255.63% YoY).
• Operating cash flow (Q2 2025): CNY 348.74 million (up 13.87% YoY).
• Cash from investing activities (Q2 2025): -CNY 47.58 million (down 73.00% YoY).
• Cash from financing activities (Q2 2025): -CNY 404.94 million (down 97.62% YoY).

Interpreting the data:

• The 42.18% decline in cash and short-term investments to CNY 413.15 million signals reduced cushion for short-term obligations despite improved operating cash flow.
• Operating cash flow rose 13.87% to CNY 348.74 million, supporting a sharp improvement in free cash flow (+255.63% to CNY 302.84 million), suggesting more efficient conversion of earnings into cash.
• Negative investing cash flow of -CNY 47.58 million (down 73.00% YoY) points to lower investment outlays or asset dispositions compared with the prior year.
• Substantial outflow in financing activities (-CNY 404.94 million, down 97.62% YoY) likely reflects debt repayments, dividend/return of capital actions, or reduced external funding - contributing to the negative net change in cash.
• Overall, operating strength and free cash flow improvements contrast with shrinking cash reserves and heavy financing outflows, highlighting a trade-off between internal cash generation and external cash use.

For context on the company's stated direction and principles, see: Mission Statement, Vision, & Core Values (2026) of Xi'an International Medical Investment Company Limited.

Xi'an International Medical Investment Company Limited (000516.SZ) - Valuation Analysis

Key market and valuation metrics for Xi'an International Medical Investment Company Limited (000516.SZ) provide a snapshot of how the market prices the company relative to book, sales and operating earnings, as well as its recent market performance and trading activity.

• Price-to-Book (PB): 3.38 - indicates the market values the firm at more than three times its book equity.
• Price-to-Sales (PS): 2.45 - the market pays CNY 2.45 for each CNY 1 of revenue.
• Enterprise Value / Sales (EV/Sales): 3.31 - enterprise-level valuation relative to revenue.
• EV/EBITDA: 35.06 - suggests a high multiple on operating cash earnings.
• Market Capitalization (as of 2025-08-01): CNY 12.25 billion - a 15.64% increase year-over-year.
• Beta: 0.90 - slightly less volatile than the market.
• 52‑week price change: +16.95% - positive price appreciation over the past year.
• RSI: 24.84 - currently in lower momentum/near-oversold territory.
• 20‑day average volume: 27,578,614 shares - indicates robust trading liquidity.

• Valuation context: PB 3.38 and PS 2.45 combined with EV/EBITDA 35.06 point to a company priced for growth but with elevated earnings multiple risk if EBITDA expands slowly.
• Market-cap growth of 15.64% Y/Y supports the premium multiples; beta 0.90 and strong average volume reduce volatility and execution risk for investors.
• Technical/momentum mix: 52‑week +16.95% versus an RSI of 24.84 suggests medium-term appreciation but near-term oversold conditions - warrants monitoring of catalysts or earnings revisions.
• Use EV/Sales (3.31) to compare with peers when capital structure or cash levels differ; EV/EBITDA (35.06) should be stress-tested against projected EBITDA growth to assess fairness of current pricing.

Xi'an International Medical Investment Company Limited (000516.SZ) - Risk Factors

Xi'an International Medical Investment Company Limited faces several material financial risk factors that investors should weigh carefully. The company's balance sheet leverage, constrained liquidity, negative operating performance, and weakened interest coverage combine to elevate short- to medium-term financial risk despite a below-market beta.

• Debt structure: total debt CNY 4.45 billion; debt-to-equity ratio 1.39 - indicating debt substantially exceeds shareholders' equity.
• Liquidity stress: current ratio 0.28 and quick ratio 0.25 - signals potential difficulty meeting near-term obligations without refinancing or asset sales.
• Profitability and operations: trailing twelve months (TTM) operating income -CNY 261.53 million and net profit margin -5.65% - ongoing negative operations and declining profitability.
• Coverage shortfall: interest coverage ratio -1.66 - EBIT is negative, implying operating cash flows insufficient to cover interest expense.
• Market signals: beta 0.90 (lower volatility) but RSI 24.84 - technical indicator suggests the stock is potentially oversold, reflecting market pessimism.

Key investor considerations include refinancing capacity, covenant exposure, timeline to return to positive EBIT, and sensitivity of solvency to revenue declines or interest rate shifts.

• Monitor upcoming debt maturities and access to capital markets or bank facilities.
• Assess management plans to restore operating income and margin improvement.
• Watch liquidity metrics and any asset disposals or equity injections.
• Consider technical signals (RSI) alongside fundamental stress when timing entry or exit.

Reference: Mission Statement, Vision, & Core Values (2026) of Xi'an International Medical Investment Company Limited.

Xi'an International Medical Investment Company Limited (000516.SZ) - Growth Opportunities

• Analyst forecasts: earnings expected to grow 88.3% per annum and revenue 14.6% per annum over the next three years, reflecting strong margin expansion potential.
• EPS trajectory: EPS is projected to rise 86.5% per annum over the next three years, implying significant earnings per share accretion for shareholders.
• ROE outlook: return on equity is forecasted at 0.3% in three years, indicating current low capital efficiency that may improve if net income scales faster than equity growth.
• Market position: the company holds approximately 15% market share in China's medical device sector, providing a solid platform for cross-selling and scale economies.
• Strategic partnerships: initiated collaborations with local healthcare providers, estimated to expand product reach by ~30% within the next year.
• Joint ventures & R&D investment: management is considering joint ventures in medical technology/research targeting a cumulative investment of CNY 300 million to accelerate product pipeline and innovation.

• Customer & channel impact: a ~30% increase in product reach from local provider partnerships is likely to accelerate recurring revenue and shorten commercialization cycles for new devices.
• Capital deployment: CNY 300 million earmarked for JVs and R&D can unlock higher-margin medical-technology revenues if allocated to scalable platforms and regulatory success.
• Valuation implications: the large disparity between double-digit EPS growth forecasts and a near-zero ROE forecast suggests a transitional phase where earnings are ramping before full capital efficiency recovery.